Panitumumab
Colon Adenocarcinoma
IFOM ETS - The AIRC Institute of Molecular Oncologymonoclonal_antibodyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
42 Active assets in the Colon Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Xaliplatin Sun Yat-sen University | Phase 3 | BBB |
Fluorouracilum Merck Sharp & Dohme LLC | Phase 3 | BBB |
Irinotecan Sun Yat-sen University | Phase 3 | BBB |
Cetuximab Merck Sharp & Dohme LLC | Phase 3 | BB |
Nivolumab IFOM ETS - The AIRC Institute of Molecular Oncology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Panitumumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →